Completed PHASE1 INTERVENTIONAL 5-arm NCT00106145

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

A Phase I Study of MK0752, a Notch Inhibitor, in Patients With Metastatic or Locally Advanced Breast Cancer and Other Solid Tumors

Sponsor: Merck Sharp & Dohme LLC

Conditions Advanced Breast Cancer Other Solid Tumors

Interventions Comparator: MK0752, Notch Inhibitor Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg Comparator: MK0752, Notch Inhibitor - 450 mg

Updated 7 times since 2017 Last updated: Jan 29, 2015 Started: Apr 30, 2005 Primary completion: Aug 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00106145, this PHASE1 trial focuses on Advanced Breast Cancer and Other Solid Tumors and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.